Hyloris Pharmaceuticals Past Earnings Performance
Past criteria checks 0/6
Hyloris Pharmaceuticals's earnings have been declining at an average annual rate of -17.1%, while the Pharmaceuticals industry saw earnings growing at 12.9% annually. Revenues have been growing at an average rate of 38.2% per year.
Key information
-17.1%
Earnings growth rate
-4.0%
EPS growth rate
| Pharmaceuticals Industry Growth | 12.4% |
| Revenue growth rate | 38.2% |
| Return on equity | -38.2% |
| Net Margin | -190.8% |
| Next Earnings Update | 20 Mar 2025 |
Recent past performance updates
Recent updates
Here's Why We're Not Too Worried About Hyloris Pharmaceuticals' (EBR:HYL) Cash Burn Situation
Dec 21
Here's Why We're Not Too Worried About Hyloris Pharmaceuticals' (EBR:HYL) Cash Burn Situation
Aug 04Hyloris Pharmaceuticals (EBR:HYL) Is In A Strong Position To Grow Its Business
Dec 28Do Institutions Own Hyloris Pharmaceuticals SA (EBR:HYL) Shares?
Mar 08Revenue & Expenses Breakdown
How Hyloris Pharmaceuticals makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 24 | 7 | -13 | 6 | 14 |
| 31 Mar 24 | 6 | -14 | 6 | 14 |
| 31 Dec 23 | 4 | -15 | 6 | 14 |
| 30 Sep 23 | 3 | -14 | 5 | 13 |
| 30 Jun 23 | 3 | -13 | 5 | 11 |
| 31 Mar 23 | 3 | -12 | 4 | 11 |
| 31 Dec 22 | 2 | -12 | 4 | 10 |
| 30 Sep 22 | 3 | -10 | 3 | 9 |
| 30 Jun 22 | 3 | -8 | 3 | 8 |
| 31 Mar 22 | 3 | -10 | 3 | 7 |
| 31 Dec 21 | 3 | -12 | 3 | 5 |
| 30 Sep 21 | 2 | -12 | 2 | 4 |
| 30 Jun 21 | 1 | -12 | 1 | 3 |
| 31 Mar 21 | 1 | -10 | 2 | 3 |
| 31 Dec 20 | 0 | -7 | 2 | 3 |
| 30 Sep 20 | 0 | -8 | 3 | 2 |
| 30 Jun 20 | 0 | -8 | 3 | 2 |
| 31 Mar 20 | 0 | -6 | 1 | 2 |
| 31 Dec 19 | 0 | -5 | 1 | 1 |
| 31 Dec 18 | 0 | -6 | 1 | 5 |
| 31 Dec 17 | 0 | -4 | 2 | 2 |
Quality Earnings: HYL is currently unprofitable.
Growing Profit Margin: HYL is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: HYL is unprofitable, and losses have increased over the past 5 years at a rate of 17.1% per year.
Accelerating Growth: Unable to compare HYL's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: HYL is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (9.5%).
Return on Equity
High ROE: HYL has a negative Return on Equity (-38.21%), as it is currently unprofitable.
Return on Assets
Return on Capital Employed
Discover strong past performing companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/23 02:50 |
| End of Day Share Price | 2025/01/23 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Hyloris Pharmaceuticals SA is covered by 5 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Beatrice Allen | Berenberg |
| Laura Roba | Degroof Petercam |
| David Seynnaeve | Degroof Petercam |